Topic: A case of bile duct cancer with positive surgical margin obtaining lon

A case of bile duct cancer with positive surgical margin obtaining long-term survival after s-1 monotherapy

http://www.ncbi.nlm.nih.gov/pubmed/2224 … t=Abstract

Any advice or comments I give are based on personal experiences and knowledge and are my opinions only, they are not to be substituted for professional medical advice. Please seek professional advice from a qualified doctor or medical professional.

Re: A case of bile duct cancer with positive surgical margin obtaining lon

Keep in mind, S-1 therapy is only used in Asia. Western hospitals don't use it.  Western patients can't take it because of genetic differences. It's either ineffective or causes bad reaction (don't remember the exact details).

Re: A case of bile duct cancer with positive surgical margin obtaining lon

Hi,
If my info is correct. S1 will be available in the States in a couple years.and is now under studied by the FDA for its effectiveness as compare to Xeloda.

Last year,when I attended the ASCO 2011 convention there was a poster about s1, and the gentleman on duty indicated that they will try to market S1   thru a larger drug company in the States. I will get more info about S1 in the up coming ASCO2012 convention.

Basically S1 is like the  Xeloda (Capecitabine) that is current available in Europe and in the States. these are the prodrug of 5FU taken by mouth.
God bless.

Please know that my personal opinion is not intended nor implied to be a substitute for professional medical advice. If  provided, information are for educational purposes.Consult doctor is a MUST for changing of treatment plans.

4 (edited by eli Sat, 14 Jan 2012 15:07:57)

Re: A case of bile duct cancer with positive surgical margin obtaining lon

Yeah, my recollection about S-1 could be wrong. I think it comes from this study:

Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3100481/

Here's what they say about S-1:

S-1 is an oral fluoropyrimidine, consisting of tegafur, a prodrug of 5-FU, and two bio-modulators, 5-chloro-2,4-dihydroxypyridine and potassium oxonate, which maintains high serum 5-fluorouracil levels and reduces gastrointestinal toxicity. S-1 has demonstrated efficacy in a variety of solid tumors, especially in Asian patients.

The bolded part seems to suggest that S-1 is more effective in Asian patients. Doesn't mean that it's not effective in Western patients. It might be effective, just not to the same extent.

EDIT: Here's a study that confirmed that the maximum dose of S-1 tolerated by Western patients is lower than the dose tolerated by Japanese patients.

http://jco.ascopubs.org/content/23/28/6957.full